Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
Luis Pérez de Llano, Borja G. Cosío, Ignacio Lobato Astiárraga, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 79-88
Open Access | Times Cited: 18

Showing 18 citing articles:

Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort
Katrin Milger, Hendrik Suhling, Dirk Skowasch, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2701-2712.e2
Open Access | Times Cited: 40
Efficacy Assessment of Biological Treatments in Severe Asthma
Daniel Laorden, Javier Domínguez‐Ortega, David Romero, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 321-321
Open Access | Times Cited: 1
The Role of Eosinophil-Derived Neurotoxin and Vascular Endothelial Growth Factor in the Pathogenesis of Eosinophilic Asthma
Maciej Tota, Julia Łacwik, Julia Laska, et al.
Cells (2023) Vol. 12, Iss. 9, pp. 1326-1326
Open Access | Times Cited: 16
Novel biomarkers in asthma
Nikita Agrawal, Monica Kraft
Current Opinion in Pulmonary Medicine (2025)
Closed Access
Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study
John C. Thelen, Cathelijne M. van Zelst, Sigrid E. van Brummelen, et al.
Respiratory Medicine (2022) Vol. 206, pp. 107058-107058
Closed Access | Times Cited: 21
Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma
Vicente Plaza, Conxa Cañete, Christian Domingo, et al.
Open Respiratory Archives (2023) Vol. 5, Iss. 2, pp. 100231-100231
Open Access | Times Cited: 10
Biologics for severe asthma and beyond
Carlo Mümmler, Katrin Milger
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108551-108551
Closed Access | Times Cited: 9
Factors associated with suboptimal response to monoclonal antibodies in severe asthma
Luis Pérez de Llano, Nuria Marina Malanda, Isabel Urrutia, et al.
Allergy (2023) Vol. 78, Iss. 8, pp. 2305-2310
Closed Access | Times Cited: 8
Is it possible to achieve remission in severe asthma? Retrospective analysis of a four-year response in a real-life cohort treated with Mepolizumab
Jorge Correa-Borit, Daniel Laorden, Victoria Arnalich Montiel, et al.
Journal of Asthma (2024), pp. 1-6
Closed Access | Times Cited: 2
Specific Therapy for T2 Asthma
Diego Bagnasco, Elisa Testino, Stefania Nicola, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 4, pp. 593-593
Open Access | Times Cited: 11
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Francesco Menzella, Andrea Ballarin, Maria Cristina Sartor, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 11
Open Access | Times Cited: 9
Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R
Daniel Laorden, Ester Zamarrón, David Romero, et al.
Respiratory Medicine (2023) Vol. 211, pp. 107216-107216
Closed Access | Times Cited: 5
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy
Diego Bagnasco, Edoardo Savarino, Mona‐Rita Yacoub, et al.
Pharmaceutics (2023) Vol. 15, Iss. 9, pp. 2359-2359
Open Access | Times Cited: 2
Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
Huqun Li, Cuilian Guo, Chongshu Wang
Therapeutic Advances in Drug Safety (2024) Vol. 15
Open Access
Safety Profiles of Biological Therapies Used in Asthma Treatment
Gülden Paçacı Çetin, Bahar Arslan, İnsu Yılmaz
Asthma Allergy Immunology (2022) Vol. 20, Iss. 3, pp. 127-141
Open Access | Times Cited: 2
Contribution of the Remission Concept to the Treatment of Asthma
Luis Pérez-de-Llano, Iria Veiga-Teijeiro, David Dacal-Rivas
Archivos de Bronconeumología (2023) Vol. 59, Iss. 9, pp. 550-551
Open Access
Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment
Garry M. Walsh
Advances in pharmacology (2023), pp. 31-54
Closed Access
Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population
Carlos Almonacid-Sánchez, Borja G. Cosío, Andrea Trisán-Alonso, et al.
Archivos de Bronconeumología (2023) Vol. 59, Iss. 12, pp. 842-845
Open Access
Page 1

Scroll to top